GlaxoSmithKline announced that data have been received from the Phase 3 Harmony 8 study and from the event driven meta-analysis for assessment of cardiovascular safety conducted across the albiglutide clinical program investigating its use in the treatment of type 2 diabetes.
SIGN IN WITH ONE OF YOUR SOCIAL ACCOUNTS
Sign in with your MPR account
Keep me signed in Forgot your password?
REGISTER FOR FREE WITH ONE OF YOUR SOCIAL ACCOUNTS
REGISTER FOR FREE WITH A MPR ACCOUNT
Enter your MPR registration email address to receive a password reset link.
ENTER NEW PASSWORD